ArticleThe Journal of dermatology2026
Risk Factors for Cutaneous Immune-Related Adverse Events in the Japanese Population: A Retrospective Single-Center Cohort Study.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI)-driven alterations in the immune system can induce immune-related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese patients treated with at least one ICI at Yokohama City University Hospital between 2014 and 2024 and identified the risk factors for cutaneous irAEs using multivariable logistic regression analysis. Overall, 145 cutaneous irAEs were identified in 134 patients (10.9%), of which 18 (1.5%) developed grade 4 cutaneous irAEs. Statistical analysis revealed that anti-programmed cell death protein 1 (anti-PD-1) and anti-cytotoxic T-lymphocyte associated protein-4 (anti-CTLA-4) combination therapy was significantly associated with the risk of developing cutaneous irAEs compared with anti-PD-1 (odds ratio [OR] = 3.21; 95% confidence interval [CI], 1.85-5.54; p < 0.001) or anti-PD ligand 1 (OR = 4.53; 95% CI, 2.06-10.34; p < 0.001) monotherapy. A higher baseline eosinophil count (OR = 1.27; 95% CI, 1.06-1.55; p = 0.013) and melanoma (OR = 2.11; 95% CI, 1.17-3.72; p = 0.011) were associated with an increased risk of cutaneous irAEs. Furthermore, female sex (OR = 4.13; 95% CI, 1.36-13.11; p = 0.012) and high baseline monocyte count (OR = 6.68; 95% CI, 1.87-27.61; p = 0.003) were risk factors for grade 4 cutaneous irAEs. These results indicated that anti-PD-1 and anti-CTLA-4 combination therapy, high eosinophil counts, and melanoma were associated with a higher risk of developing cutaneous irAEs, whereas female sex and high monocyte counts were risk factors for severe cutaneous irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.